Meglumine antimoniate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Meglumine antimoniate API 133-51-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Meglumine antimoniate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Meglumine antimoniate
- Synonyms:
- Antimoniato de meglumina , Glucantim , Glucantime , Meglumine antimonate , Meglumine antimoniate
- Cas Number:
- 133-51-7
- DrugBank number:
- DB13732
- Unique Ingredient Identifier:
- 75G4TW236W
General Description:
Meglumine antimoniate is a chemical compound identified by the CAS number 133-51-7. It is known for its distinct pharmacological properties and applications.
Classification:
Meglumine antimoniate belongs to the class of organic compounds known as hexoses. These are monosaccharides in which the sugar unit is a is a six-carbon containing moeity, classified under the direct parent group Hexoses. This compound is a part of the Organic compounds, falling under the Organic oxygen compounds superclass, and categorized within the Organooxygen compounds class, specifically within the Carbohydrates and carbohydrate conjugates subclass.
Categories:
Meglumine antimoniate is categorized under the following therapeutic classes: Agents Against Leishmaniasis and Trypanosomiasis, Alcohols, Amino Sugars, Anti-Infective Agents, Antimony Compounds, Antiparasitic Agents, Antiparasitic Products, Insecticides and Repellents, Antiprotozoals, Carbohydrates, Hexosamines, Sugar Alcohols. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Meglumine antimoniate is a type of Antiparasitics
Antiparasitics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are used to combat parasitic infections in humans and animals. These APIs play a crucial role in the field of medicine and veterinary care by targeting and eliminating various parasites, such as protozoa, helminths, and ectoparasites.
The use of antiparasitics is essential in preventing and treating parasitic diseases, which can cause significant health issues and even be life-threatening. These APIs work by interfering with the parasite's vital biological processes, such as reproduction, metabolism, and survival mechanisms.
Pharmaceutical companies develop and manufacture a wide range of antiparasitic APIs to cater to different parasitic infections. Some common examples of antiparasitics include anthelmintics (used against intestinal worms), antimalarials (used to treat malaria), and ectoparasiticides (used to control external parasites like ticks and fleas).
The development of antiparasitic APIs requires rigorous research, including the identification of suitable targets within the parasite's biology and the formulation of effective chemical compounds. Safety and efficacy are paramount in the manufacturing of antiparasitics, ensuring that they effectively combat the targeted parasites while minimizing adverse effects on the host.
Overall, antiparasitics are vital tools in the fight against parasitic infections, benefiting both human and animal health. Through ongoing research and development, the pharmaceutical industry continues to innovate and improve antiparasitic APIs, contributing to the advancement of healthcare and the well-being of individuals and their animal companions.
